Bellicum Pharmaceuticals

Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, that develops controllable cellular immunotherapies for patients with solid tumors and rare inherited hematological cancers. The enterprise utilizes proprietary chemical induction of dimerization technology, known as GoCAR, to regulate engineered immune cells in real time, advancing specific oncology pipeline candidates such as BPX-601, BPX-603, and Rivo-cel. After raising $161 million in a 2014 initial public offering, the organization operated as a publicly traded entity on the Nasdaq exchange before eventually transitioning to the public over-the-counter market. Following a major strategic restructuring in 2023 under former chief executive officer Rick Fair, the business halted its clinical development programs and reduced its workforce to a core team of fewer than 10 employees to conserve its remaining capital. Bellicum Pharmaceuticals was originally founded in 2004 by Kevin Slawin and David Spencer.